Compare BLDR & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLDR | IOVA |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.7B |
| IPO Year | 2005 | 2008 |
| Metric | BLDR | IOVA |
|---|---|---|
| Price | $57.42 | $14.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 10 |
| Target Price | ★ $71.36 | $14.40 |
| AVG Volume (30 Days) | 2.2M | ★ 12.5M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,190,638,000.00 | N/A |
| Revenue This Year | N/A | $56.63 |
| Revenue Next Year | $2.18 | $42.41 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $49.67 | $1.76 |
| 52 Week High | $131.50 | $15.37 |
| Indicator | BLDR | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 51.74 | 59.41 |
| Support Level | $56.56 | $3.57 |
| Resistance Level | $61.82 | $15.00 |
| Average True Range (ATR) | 2.16 | 0.92 |
| MACD | 0.62 | -0.17 |
| Stochastic Oscillator | 95.83 | 58.17 |
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.